Cargando…

Nitrergic Response TO Cyclophosphamide Treatment in Blood and Bone Marrow

Daily intraperitoneal injection of cyclophosphamide (CPA) (50 mg∙kg(-1) of body weight) for 5 days resulted in reduced levels of marrow and blood cellularity, which was most pronounced in 18 days post-treatment (pt). On day 18 after CPA treatment the enhancedlevels of nitric oxide (NO) precursors an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kevorkian, G.A, Alchujyan, N.Kh, Movsesyan, N.H, Hayrapetyan, H.L, Guevorkian, A.G, Ohanyan, R.M, Dagbashyan, S.S
Formato: Texto
Lenguaje:English
Publicado: Bentham Open 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570548/
https://www.ncbi.nlm.nih.gov/pubmed/18949079
http://dx.doi.org/10.2174/1874091X00802010081
_version_ 1782160149390032896
author Kevorkian, G.A
Alchujyan, N.Kh
Movsesyan, N.H
Hayrapetyan, H.L
Guevorkian, A.G
Ohanyan, R.M
Dagbashyan, S.S
author_facet Kevorkian, G.A
Alchujyan, N.Kh
Movsesyan, N.H
Hayrapetyan, H.L
Guevorkian, A.G
Ohanyan, R.M
Dagbashyan, S.S
author_sort Kevorkian, G.A
collection PubMed
description Daily intraperitoneal injection of cyclophosphamide (CPA) (50 mg∙kg(-1) of body weight) for 5 days resulted in reduced levels of marrow and blood cellularity, which was most pronounced in 18 days post-treatment (pt). On day 18 after CPA treatment the enhancedlevels of nitric oxide (NO) precursors and metabolites (L-arginine, L-citrulline, reactive nitrogen species (RNS)) of marrow and blood cells (platelet, neutrophil, lymphocyte and monocyte) resulted from up-regulation of Ca(II)/calmodulin(CaM)-independent “inducible” NO synthase (iNOS), with a lessercontribution of Ca(II)/CaM-dependent “constitutive” cNOS isoforms to systemic NO.Biphasic response to CPA of marrow nitrergic system, i.e. both iNOS and cNOS showed significantly depressed activities, as well as diminished levels of NO metabolites on day 9 pt, suggested that signals in addition to NO might be involved in CPA-induced inhibition of hematopoesis, while a gradual increase of neutrophil and platelet NOS activity appeared to be contributed to a CPA-induced development of granulopenia, thrombocytopenia and hemorrhage.
format Text
id pubmed-2570548
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-25705482008-10-23 Nitrergic Response TO Cyclophosphamide Treatment in Blood and Bone Marrow Kevorkian, G.A Alchujyan, N.Kh Movsesyan, N.H Hayrapetyan, H.L Guevorkian, A.G Ohanyan, R.M Dagbashyan, S.S Open Biochem J Article Daily intraperitoneal injection of cyclophosphamide (CPA) (50 mg∙kg(-1) of body weight) for 5 days resulted in reduced levels of marrow and blood cellularity, which was most pronounced in 18 days post-treatment (pt). On day 18 after CPA treatment the enhancedlevels of nitric oxide (NO) precursors and metabolites (L-arginine, L-citrulline, reactive nitrogen species (RNS)) of marrow and blood cells (platelet, neutrophil, lymphocyte and monocyte) resulted from up-regulation of Ca(II)/calmodulin(CaM)-independent “inducible” NO synthase (iNOS), with a lessercontribution of Ca(II)/CaM-dependent “constitutive” cNOS isoforms to systemic NO.Biphasic response to CPA of marrow nitrergic system, i.e. both iNOS and cNOS showed significantly depressed activities, as well as diminished levels of NO metabolites on day 9 pt, suggested that signals in addition to NO might be involved in CPA-induced inhibition of hematopoesis, while a gradual increase of neutrophil and platelet NOS activity appeared to be contributed to a CPA-induced development of granulopenia, thrombocytopenia and hemorrhage. Bentham Open 2008-06-03 /pmc/articles/PMC2570548/ /pubmed/18949079 http://dx.doi.org/10.2174/1874091X00802010081 Text en © Kevorkian et al.; Licensee Bentham Open http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Kevorkian, G.A
Alchujyan, N.Kh
Movsesyan, N.H
Hayrapetyan, H.L
Guevorkian, A.G
Ohanyan, R.M
Dagbashyan, S.S
Nitrergic Response TO Cyclophosphamide Treatment in Blood and Bone Marrow
title Nitrergic Response TO Cyclophosphamide Treatment in Blood and Bone Marrow
title_full Nitrergic Response TO Cyclophosphamide Treatment in Blood and Bone Marrow
title_fullStr Nitrergic Response TO Cyclophosphamide Treatment in Blood and Bone Marrow
title_full_unstemmed Nitrergic Response TO Cyclophosphamide Treatment in Blood and Bone Marrow
title_short Nitrergic Response TO Cyclophosphamide Treatment in Blood and Bone Marrow
title_sort nitrergic response to cyclophosphamide treatment in blood and bone marrow
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570548/
https://www.ncbi.nlm.nih.gov/pubmed/18949079
http://dx.doi.org/10.2174/1874091X00802010081
work_keys_str_mv AT kevorkianga nitrergicresponsetocyclophosphamidetreatmentinbloodandbonemarrow
AT alchujyannkh nitrergicresponsetocyclophosphamidetreatmentinbloodandbonemarrow
AT movsesyannh nitrergicresponsetocyclophosphamidetreatmentinbloodandbonemarrow
AT hayrapetyanhl nitrergicresponsetocyclophosphamidetreatmentinbloodandbonemarrow
AT guevorkianag nitrergicresponsetocyclophosphamidetreatmentinbloodandbonemarrow
AT ohanyanrm nitrergicresponsetocyclophosphamidetreatmentinbloodandbonemarrow
AT dagbashyanss nitrergicresponsetocyclophosphamidetreatmentinbloodandbonemarrow